Podd: Smart Biotech Scientist | Master Bioprocess CMC Development, Biologics Manufacturing & Scale-up for Busy Scientists

130: Revolutionizing Cell Therapy Manufacturing: Reducing Costs to Reach More Patients with Jason Foster - Part 2

20 februari 2025 | 20 min

The intricacies of tech transfer and the challenges of scaling manufacturing processes are often underestimated in the biotechnology industry. Understanding these complexities is crucial for translating innovative scientific breakthroughs into commercially viable products.

In the second part of the conversation with Jason Foster, CEO of Ori Biotech, host David Brühlmann explores the complexities of cell therapy manufacturing. Their discussion highlights key challenges, including tech transfer, scale-out strategies, and the crucial role of commercial strategy alongside scientific excellence.

Jason also revealed a groundbreaking approach in the cell therapy space. He detailed how Ori's IRO® platform can process multiple patient doses simultaneously, enabling treatment for 30 patients in parallel within just 1,000 square feet of clean room space. This innovative method drastically reduces clean room requirements by about 95% and facility sizes by approximately 50%, significantly cutting costs associated with building and operating large-scale facilities.

As Jason emphasized, this shift not only accelerates access to groundbreaking therapies but also provides a sustainable model for scaling cell therapy production.

Key Points to Remember:

Integrated Approach: Scientists should look beyond their specialized areas and understand the requirements of subsequent bioprocessing stages to maximize patient impact.
Technological Evolution: Advancing distributed manufacturing and enhancing in-line analytics are essential steps to revolutionize the biotech landscape.
Commercial Viability: Prioritizing commercial feasibility alongside safety and efficacy in preclinical development can prevent costly late-stage setbacks.

This episode of the Smart Biotech Scientist underscores the complexities and transformative potential of cell therapy manufacturing. As the industry continues to innovate, integrating commercial viability, flexibility, and advanced manufacturing solutions will be critical. By breaking down silos and fostering collaboration, we can accelerate the development of life-saving therapies—ensuring they reach patients faster and more efficiently.

Connect with Jason Foster

LinkedIn: https://www.linkedin.com/in/jasoncfoster

Oribiotech: https://oribiotech.com

Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biotherapeutics better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech/p/book-a-11-call-with-me-j4vhuo6t

129: Revolutionizing Cell Therapy Manufacturing: Reducing Costs to Reach More Patients with Jason Foster - Part 1

18 februari 2025 | 22 min

Send us a text

One of the most urgent challenges in modern medicine is making cell and gene therapies widely accessible. These therapies, while groundbreaking in their safety and efficacy, often fall short when it comes to reaching patients. The reasons are manifold—high manufacturing costs, logistical complexities, and inefficiencies in the production pipeline.

We're joined by Jason Foster, CEO and Executive Director of Ori Biotech, a company that's revolutionizing cell and gene therapy manufacturing through automation and innovative approaches.

Jason sheds light on the technical bottlenecks that limit patient access to life-saving therapies and discusses how an integrated, holistic view of the development chain could make a significant difference. From the complexities of centralized manufacturing and the interconnectedness of the supply chain, to specific technical solutions Ori Biotech has developed, we explore the multi-faceted issues and potential solutions in making these advanced therapies more reachable.

Here are three key takeaways from our conversation:

Holistic Development Chain: Jason emphasizes the importance of integrating all stakeholders in the development chain, ensuring everyone understands what happens before and what needs to happen next to improve the overall process.
Technical Bottlenecks & Solutions: We delved into various technical bottlenecks, including centralized manufacturing and logistical complexities. Jason highlighted how Ori Biotech is addressing these issues through automation and reducing manual labor, which can cut manufacturing costs by 50%.
Impact on Accessibility: It's alarming that only 3-5% of patients who need CAR-T therapies have access to them. Jason's mission with Ori Biotech is to transform this narrative by enabling widespread access to these life-saving therapies through innovative manufacturing solutions.

As cell and gene therapies stand poised to revolutionize cancer and rare disease treatment, the focus must shift toward overcoming manufacturing constraints. By integrating automation and aiming for decentralized models, companies like Ori Biotech offer a glimpse into a future where these revolutionary treatments are accessible to all who need them.

Fascinated by Cell Therapy? Hear from top experts in these two episodes!

Episodes 11 and 12: From Lab to Patient: Steve Oh’s Guide to Mastering Cell Therapy Process Development
Episodes 21 and 22: Unleashing Effective QbD Strategies to Master Cell Therapy with Shin Kawamata

Connect with Jason Foster

LinkedIn: https://www.linkedin.com/in/jasoncfoster

Oribiotech: https://oribiotech.com

Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biotherapeutics better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech/p/book-a-11-call-with-me-j4vhuo6t

128: The 7 Hidden Innovation Habits That Top Biotech Scientists Use Daily - Part 2

13 februari 2025 | 18 min

Send us a text

The world of bioprocess development in biotechnology is evolving at an unprecedented pace, driven by the quest for breakthrough innovations. While new technologies play a significant role, what truly sets successful innovators apart are fundamental habits that foster an environment ripe for groundbreaking discoveries.

In today's discussion, we'll delve into three essential habits that, when combined with the four habits previously discussed, can redefine your approach to bioprocess development. Additionally, we'll wrap up with a bonus tip that has the potential to revolutionize your career.

Challenge the Status Quo - In any scientific endeavor, particularly in biotech, a common pitfall is accepting established processes as the best or only methods. The fifth habit to cultivate is the continuous challenging of the status quo. When was the last time you scrutinized your standard operating procedures and wondered why they are the way they are?
Embrace Continuous Learning - Innovation in biotech is characterized by rapid advancements, and staying ahead demands continuous learning. According to a 2023 EDX survey, nearly half of today's workplace skills will be obsolete by 2025, primarily due to AI advancements. Hence, the sixth habit is to never stop learning.
Harness the Power of Passion - At the core of every great innovation is passion. The seventh habit revolves around the deep sense of purpose that drives scientific pursuits. Beyond the routine aspects of bioprocess development, what truly fuels your ambition?

Finally, a game-changing career strategy known as Strategic Cross-Pollination Networking can significantly enhance your innovative capabilities. This goes beyond traditional networking, focusing on building connections across various domains to foster innovative solutions.

Innovation in bioprocess development is not about daily eureka moments but about the consistent application of these habits. Small, persistent efforts can cumulatively lead to transformative results in this rapidly evolving field.

If you found these insights valuable, share them with your colleagues. Ready to fast-track your product and technology development? As a strategic advisor to biotech leaders, we can help you eliminate costly delays and optimize your path to market.

Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biotherapeutics better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech/p/book-a-11-call-with-me-j4vhuo6t

127: The 7 Hidden Innovation Habits That Top Biotech Scientists Use Daily - Part 1

11 februari 2025 | 16 min

Send us a text

In the fast-paced and highly regulated world of biotech development, maintaining an innovative spirit can sometimes feel like a Herculean task. Between optimizing cell culture processes and navigating strict regulatory requirements, it’s no wonder many scientists feel the weight of daily operations pressing down on their creativity. However, fostering innovation is crucial for breakthroughs in our field.

David Brühlmann shares practices that have transformed how scientists approach complex challenges in our field.

Here are the first four habits that can reshape your approach to bioprocess development.

Cultivate Deep Curiosity: Curiosity is the cornerstone of scientific discovery. However, it’s not just about a broad interest in science. The type of curiosity that drives innovation is the kind that goes beyond initial observations. It's the kind that makes you question what's happening inside the cell culture and strive to understand phenomena at a fundamental level.
Connect the Dots: Innovation often comes from connecting seemingly unrelated ideas. Drawing connections between different facts or events can lead to a better understanding and new approaches to complex challenges.
Embrace Calculated Risks: In a GMP environment, risk-taking may sound contradictory. However, calculated risks are essential for innovation. It's about carefully evaluating opportunities and understanding their potential impact before acting.
Practice Persistence: Persistence is a key ingredient for innovation, especially during challenging times. Experimentation often involves setbacks and unexpected results, but each failure is a learning opportunity.

Fostering innovation in biotech development is a multifaceted process that requires curiosity, the ability to connect dots, calculated risks, persistence, collaboration, digital tools, and continuous learning. By integrating these habits into your work routine, you can unlock new potentials and drive breakthroughs in the biotech field. Remember, breakthroughs often come from embracing the complex nature of bioprocess development and continuously exploring, questioning, and innovating.

Don't miss our next episode, where we’ll reveal the final three habits!

Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biotherapeutics better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech/p/book-a-11-call-with-me-j4vhuo6t

126: How to Enhance Cell Engineering Using Mechanical Intracellular Delivery with Armon Sharei - Part 2

6 februari 2025 | 21 min

Send us a text

As biotechnology rapidly evolves, cell therapies are emerging as a groundbreaking frontier with the potential to transform medicine. In this episode of the Smart Biotech Scientist Podcast, host David Brühlmann speaks with Armon Sharei, founder and CEO of Portal Bio, about the complexities, challenges, and future of cell therapies.

Cell therapies could revolutionize medicine in ways similar to antibiotics and vaccines. However, the current manufacturing process is costly and time-consuming.

Armon Sharei envisions a future where point-of-care production makes these therapies more accessible, even at the patient's bedside. This approach could not only benefit developed countries but also emerging markets.

Armon suggests that cell therapies could be as transformative as antibiotics and vaccines, with the potential to address complex diseases like cancer and autoimmune disorders. These therapies could precisely target tumors, correct dysfunctions in autoimmune diseases, and regenerate tissues in conditions like Parkinson's.

Key Takeaways:

Cell Therapies as the Future: Armon emphasizes that cell therapies, like antibiotics and vaccines, offer high efficacy with minimal toxicity. They can address complex diseases such as tumors and autoimmune disorders.
Simplifying Manufacturing: Current manufacturing methods are expensive and slow. Portal Bio’s point-of-care approach could streamline production, reducing both time and costs.
Expanding Accessibility: Making cell therapies more accessible requires technological advances as well as changes in regulatory and quality standards to lower costs and make treatments available globally.

As technology advances, the future of cell therapies looks promising. Armon believes point-of-care cell therapies will bring sophisticated treatments directly to patients, transforming healthcare.

Connect with Armon Sharei

LinkedIn: https://www.linkedin.com/in/armonsharei/

Portal: https://www.portal.bio

Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biotherapeutics better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech/p/book-a-11-call-with-me-j4vhuo6t

125: How to Enhance Cell Engineering Using Mechanical Intracellular Delivery with Armon Sharei - Part 1

4 februari 2025 | 22 min

Send us a text

Intracellular delivery is essential for advancing research and clinical applications, yet it presents unique challenges when working with different cell types and biomolecules.

In a recent episode of the Smart Biotech Scientist podcast, David Brühlmann spoke with Armon Sharei, the founder and CEO of Portal Bio, about the future of cell therapy, the hurdles of intracellular delivery, and groundbreaking innovations in drug screening.

Armon’s journey began at MIT, where his initial focus on chemical engineering evolved into a passion for cell engineering. While exploring innovative methods for introducing materials into cells, he discovered a novel mechanism: squeezing cells to temporarily disrupt their membranes, allowing materials to diffuse in.

Armon explained that optimizing delivery parameters - such as pore size and the speed at which cells pass through specialized membranes - can significantly enhance efficiency. "If you've optimized it, one time is enough," he noted. "We can get above 80% delivery and viability pretty easily for most cell types." He emphasized the importance of tailoring pore sizes to specific cell types, such as smaller pores for T cells compared to stem cells. Additionally, the flow speed of cells through the membrane is critical; moving too slowly renders the process ineffective, while moving too quickly can damage the cells.

Tune in to this episode to find out more about:

Addressing Intracellular Delivery Challenges: Portal Bio’s breakthrough technology uses mechanical deformation to open a cell’s lipid bilayer, allowing materials to diffuse in. This approach overcomes the limitations of traditional methods like electroporation or nanoparticle-mediated delivery, which often depend on molecular charge or risk damaging cells.
Delivering a Wide Range of Molecules: Portal Bio’s technology is versatile, capable of delivering DNA, RNA, peptides, proteins, and more. Unlike methods tailored to specific molecules, this platform supports diverse applications. For instance, RNA operates in the cytoplasm, making delivery straightforward, while CRISPR complexes require nuclear localization sequences to enable gene editing in the nucleus.
Streamlining Drug Screening: Portal Bio’s technology also revolutionizes drug screening. Traditional approaches often struggle with impermeable small molecules, leading to lengthy and uncertain drug development processes. By enabling high-throughput screening, Portal Bio accelerates the evaluation of numerous drug candidates, identifying promising options before chemical modifications are necessary.

As bioprocesses grow more advanced, the demand for efficient and versatile intracellular delivery methods becomes increasingly critical. Armon’s insights underscore a transformative shift in the technologies and processes shaping the future of cell therapy and bioprocessing.

Connect with Armon Sharei

LinkedIn: https://www.linkedin.com/in/armonsharei

Portal: https://www.portal.bio

Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biotherapeutics better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech/p/book-a-11-call-with-me-j4vhuo6t

124: Manufacturability: Why Most Protein Candidates Fail (And How to Pick Winners Early) with Susan Sharfstein - Part 2

30 januari 2025 | 18 min

Send us a text

In part two of our insightful conversation, Dr. Susan Sharfstein builds on our previous discussion of developability assessment to explore how AI is revolutionizing protein manufacturability predictions.

As a Professor of Nanoscale Science and Engineering at the University of Albany, she shares groundbreaking insights from her collaboration with DeepSeq AI, demonstrating how artificial intelligence is transforming our ability to assess and predict protein manufacturability early in development.

Key Takeaways:

Discover how AI tools are enhancing traditional developability assessments by predicting protein expression and stability before entering the lab
Learn why integration of experimental validation with AI predictions is crucial for successful manufacturability assessment, and how industry partnerships are making this possible at unprecedented scale
Understand how the synergy between AI, DNA synthesis capabilities, and robotics is creating a "positive spiral" that will accelerate protein manufacturing innovation

Whether you're involved in candidate selection, process development, or curious about AI's impact on developability assessment, this episode offers valuable insights into the future of protein manufacturing. Plus, Dr. Sharfstein shares invaluable career advice for emerging biotech scientists.

Join us to explore how AI is reshaping developability assessment and learn why this field continues to offer life-changing possibilities for patients worldwide.

Connect with Susan Sharfstein:

LinkedIn: https://www.linkedin.com/in/susan-sharfstein-b7552111/

College of Nanotechnology, Science, and Engineering, University at Albany: https://www.albany.edu/cnse

Next Steps:

Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech/p/book-a-11-call-with-me-j4vhuo6t

123: Manufacturability: Why Most Protein Candidates Fail (And How to Pick Winners Early) with Susan Sharfstein - Part 1

28 januari 2025 | 23 min

Send us a text

In this eye-opening episode, we dive deep into the critical yet often overlooked world of protein manufacturability with Dr. Susan Sharfstein, Professor of Nanoscale Science and Engineering at the University of Albany. As part of the broader developability assessment process, manufacturability evaluation helps determine whether a therapeutic candidate can be successfully produced at commercial scale.

Drawing from her extensive experience in bioprocessing and cell culture technology, Dr. Sharfstein reveals why seemingly promising protein candidates can fail during manufacturing—and how to spot these issues early.

Key Takeaways:

Discover why efficacy isn't enough: Learn how to evaluate protein candidates beyond clinical performance to ensure manufacturing success
Master early-stage assessment: Understand the critical parameters that can make or break successful scale-up, from cell line selection to protein folding
Future-proof your development: Gain insights into how AI is transforming protein manufacturability assessment and what this means for process development

Whether you're selecting protein candidates or optimizing your bioprocess, this episode offers invaluable guidance for making smarter decisions earlier in development. Join us to learn how to bridge the gap between discovery and manufacturing success.

Listen now to transform how you approach protein manufacturability and save valuable time and resources in your development journey.

Connect with Susan Sharfstein:

LinkedIn: https://www.linkedin.com/in/susan-sharfstein-b7552111/

College of Nanotechnology, Science, and Engineering, University at Albany: https://www.albany.edu/cnse

Next Steps:

Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech/p/book-a-11-call-with-me-j4vhuo6t

122: The Transformative World of Digital Solutions in Bioprocessing with Simon Wieninger - Part 2

23 januari 2025 | 18 min

Send us a text

In the second part of this conversation on digital solutions in bioprocessing, David Brühlmann and Simon Wieninger, Business Manager Digital Solutions at Eppendorf Group, discuss real-world examples of labs revolutionizing their workflows through smart digitalization. From real-time data monitoring to intercontinental data sharing, Simon highlights the practical benefits and exciting future potential of digital technologies in bioprocessing.

Missed Part 1? In the previous episode, Simon Wieninger from Eppendorf Group addressed data silos, cloud technology, and security in biotech. Catch up on that episode before diving into Part 2!

Key highlights from the episode:

Choosing the Right Tools: Simon emphasized the importance of selecting the right digital tools and technologies to focus on what brings the most value, particularly in the bioreactor space. Real-time data access, even from your mobile device while walking your dog, is now possible!
Data Sharing Across Sites: Simon shared a fascinating case where a U.S.-based biotech company and their CDMO in Germany shared real-time data through the cloud, breaking down silos and enabling collaborative analysis. Imagine the possibilities for your company!
Looking to the Future: We explored the exciting potential of integrating bioprocessing data with clinical outcomes, particularly in cell and gene therapy. This holistic approach can revolutionize patient care and therapy development.

As Simon succinctly puts it, scientists should focus on what they do best - biology. The burden of managing digital technologies should not overshadow their primary research and development activities. With specialized tools and expert support, biotechnologists can achieve greater efficiency and innovation without getting bogged down by technological complexities.

The conversation between Simon Wieninger and David Brühlmann illuminates the transformative potential of digital tools in bioprocessing. From real-time monitoring to data harmonization and cross-site collaboration, these technologies are paving the way for more efficient and innovative bioprocessing practices.

By strategically adopting these tools, scientists can focus on groundbreaking research, ultimately accelerating the development and delivery of life-saving therapies.

Connect with Simon Wieninger:

LinkedIn: https://www.linkedin.com/in/dr-simon-wieninger-45b546182

Eppendorf Group: https://www.eppendorf.com

Next Steps:

Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech/p/book-a-11-call-with-me-j4vhuo6t

121: The Transformative World of Digital Solutions in Bioprocessing with Simon Wieninger - Part 1

21 januari 2025 | 23 min

Send us a text

Digital transformation is reshaping industries worldwide, and biotech is no exception. With the integration of cloud technologies, AI, and data harmonization, bioprocessing is becoming smarter, more efficient, and more innovative. Catching up with digital revolutions in other sectors, biotech now stands at the threshold of tremendous change.

In this episode of the Smart Biotech Scientist Podcast, David Brühlmann sat down with Simon Wieninger, Business Manager Digital Solutions at Eppendorf Group, to discuss the digital revolution sweeping through bioprocessing labs. From bioreactors to data lakes, Simon sheds light on the urgent need for a data-driven approach in biotech and how digital transformation is set to reshape the industry.

Here are the top three key takeaways:

Breaking Down Silos: The importance of consolidating data in one place to facilitate better analysis and collaboration across departments.
Leveraging Cloud Technology: Simon emphasized that the biotech industry is ready to embrace cloud technologies for enhanced data management.
Data Security Concerns: Addressing the common misconception about cloud security, Simon reassured that robust measures are in place to protect bioprocess data, making it as secure as banking data.

The move towards centralized data storage, the integration of AI, and strategic collaborations are critical steps in this journey. The industry is poised for transformation, and as Simon aptly put it, “step by step,” we can harness the full potential of these digital solutions. As biotech continues to evolve, the fusion of technology and biological science will undoubtedly lead to groundbreaking advancements, streamlining processes, and unlocking new possibilities in the field.

Connect with Simon Wieninger

LinkedIn: https://www.linkedin.com/in/dr-simon-wieninger-45b546182

Eppendorf Group: https://www.eppendorf.com

Enjoyed this episode? Don’t miss these related discussions:

Episode 100: From Raw Data to Actionable Insights: Unlocking the Power of Process Models with Fabian Feidl, co-founder and CTO of DataHow
Episode 05: Hybrid Modeling: The Key to Smarter Bioprocessing with Michael Sokolov, the co-founder and COO of DataHow

Next Steps:

Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech/p/book-a-11-call-with-me-j4vhuo6t

120: Innovating Protein Purification Using Synthetic Organelles and AI with Haotian Guo - Part 2

16 januari 2025 | 21 min

Send us a text

In the ever-evolving world of biotechnology, the integration of artificial intelligence (AI) and synthetic biology is driving unprecedented advancements. This transformative power was the focus of this podcast episode of the Smart Biotech Scientist, where host David Brühlmann engaged in a thought-provoking conversation with Haotian Guo, CEO and Founder of Ailurus on the role of AI in bioprocessing, the significance of wet lab validation, and the exciting future of programmable biology.

The conversation with Haotian Guo sheds light on the profound impact AI is having on the field of biotechnology. AI's role as a "co-pilot" in scientific endeavors has enabled researchers to tackle complex problems with greater efficiency and accuracy. Haotian Guo shares: "AI helps us tremendously with tasks that are tedious and time-consuming for humans, such as reading and summarizing vast amounts of scientific literature. This capability allows scientists to focus on higher-order thinking and problem-solving."

Key insights for this conversation:

AI as Co-Pilot: Discover how Ailurus leverages AI to enhance research workflows. Haotian emphasizes using AI to read and analyze massive amounts of scientific literature, making it an invaluable co-pilot in the lab.
Synthetic Biology Meets AI: Learn how synthetic biology combined with AI-driven models is opening new horizons for developing DNA designs and optimizing protein engineering. This fusion of biology and technology is proving to be a game-changer.
Challenges in Biotech: Haotian candidly discusses the ongoing challenges, such as the need for wet lab validation and the high costs associated with data generation. Despite these hurdles, the potential for AI to streamline processes is immense.

While the integration of AI and synthetic biology offers tremendous opportunities, Haotian Guo advises caution, particularly for those considering venturing into a biotech startup. He acknowledges the high-risk nature of startups, especially in an unpredictable economic landscape.

However, he also underscores the importance of perseverance and preparedness, qualities crucial for navigating the biotech industry's challenges.

In conclusion, Haotian Guo's insights paint a compelling picture of the future. The synergy between AI and biotech holds the promise of smarter, more efficient, and more accessible scientific research. By leveraging the strengths of both computational and experimental approaches, the biotech community is poised to achieve remarkable breakthroughs, transforming the landscape of healthcare and beyond.

Connect with Haotian Guo:

LinkedIn: www.linkedin.com/in/haotian-guo

Ailurus: www.ailurus.bio

Next Steps:

Wondering how to develop bioprocesses with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech/p/book-a-11-call-with-me-j4vhuo6t

119: Innovating Protein Purification Using Synthetic Organelles and AI with Haotian Guo - Part 1

14 januari 2025 | 20 min

Send us a text

Biotechnology is rapidly evolving as innovation addresses real-world needs. At the cutting edge of this evolution, synthetic biology and AI-driven protein design are revolutionizing our approach to complex processes like protein purification.

In this episode of the Smart Biotech Scientist podcast, host David Brühlmann talks with Haotian Guo, CEO and Founder of Ailurus, about the modern advancements in synthetic organelles and their transformative impact on protein purification.

Haotian Guo introduces a groundbreaking approach inspired by nature’s processes. Instead of relying solely on chromatography, synthetic biology mimics how organelles in cells, like beta cells purifying insulin, naturally segregate and process proteins. This innovation simplifies and optimizes bioprocessing, offering a more efficient alternative to traditional techniques.

Key takeaways from this conversation:

Revolutionary Advances in Protein Purification: Haotian discusses the innovative use of synthetic membrane-less organelles to simplify and enhance protein purification processes, drawing inspiration from natural cellular mechanisms.
Combining AI with Synthetic Biology: Learn how the integration of AI and biotechnology can accelerate advancements and create more efficient bioprocesses, unlocking potential for rapid development in biologics.
Scalability and Practical Applications: Insight into how these new technologies are being scaled from lab environments to industrial applications, maintaining high purity and yield, and the potential roadblocks and solutions encountered along the way.

Through innovation rooted in imitation of natural processes and amplified by the power of AI, the future of protein purification looks drastically simplified, more efficient, and scalable. Synthetic organelles represent a leap forward, challenging the age-old techniques that have long dominated the field.

Companies like Ailurus are not just contributing new tools but reshaping the roadmap for bioprocess development. As we stand on the brink of these technological advancements, the collaborative synergy between synthetic biology and artificial intelligence is setting the stage for revolutionary impacts across the biotech landscape.

This podcast episode is filled with eye-opening insights and practical takeaways for anyone in the biotech or pharmaceutical industries. Whether you're an academic, a seasoned industry professional, or simply curious about the field, you'll find valuable perspectives to explore.

Connect with Haotian Guo:

LinkedIn: www.linkedin.com/in/haotian-guo

Ailurus: www.ailurus.bio

Next Steps:

Wondering how to develop bioprocesses with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech/p/book-a-11-call-with-me-j4vhuo6t

118: Critical Bottlenecks and Breakthroughs in Cell Line Development with Andrea Gough - Part 2

9 januari 2025 | 15 min

Send us a text

In the second part of our conversation with Andrea Gough, Senior Director for Advanced Instruments’ Solentim Portfolio, we’ll explore how AI and machine learning have, in recent years, begun to transform various aspects of biotechnology, including cell line development (CLD). Andrea shares insights into how these cutting-edge technologies are being applied to the early stages of clone selection.

AI's capability to analyze images and classify clone viability is another breakthrough. Feeding thousands of images into AI systems allows for efficient and accurate decision-making, reducing the workload on scientists.

Here are three key takeaways from our conversation:

Leverage AI and Machine Learning: Integrate AI to streamline clone selection and optimize cell line development processes. AI can identify key phenotypic identifiers and predict the best clones, driving efficiency and productivity.
Diversify Expression Systems: While CHO cells dominate the protein therapy space, exploring alternative systems like HEK cells, MSCs, IPSCs, and even insect cells can offer unique benefits and improve gene therapy productions.
Maintain Comprehensive Documentation: Ensure rigorous tracking and documentation of all processes. From certificates of analysis to raw image data, having meticulous records will safeguard your development process and aid compliance with regulatory standards.

Tune in to the full episode for more insights on overcoming challenges in cell line development and tips for setting up successful bioprocessing workflows!

Connect with Andrea Gough

LinkedIn: www.linkedin.com/in/andrea-gough-72915282

Advanced Instruments: www.aicompanies.com

Next Steps:

Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech/p/book-a-11-call-with-me-j4vhuo6t

117: Critical Bottlenecks and Breakthroughs in Cell Line Development with Andrea Gough - Part 1

7 januari 2025 | 24 min

Send us a text

Cell line development (CLD) is a cornerstone of biologics production. This intricate process involves establishing a cell line capable of consistently producing a desired product, such as a therapeutic protein. While advancing science has refined numerous aspects of CLD, bottlenecks still exist, perpetuating challenges for scientists and industry professionals.

In this episode of the Smart Biotech Scientist Podcast, Andrea Gough, Senior Director for Advanced Instruments’ Solentim Portfolio, shared her extensive insights into the critical bottlenecks and innovative breakthroughs in cell line development.

Here are three key takeaways from this episode:

Understanding the DNA Integration Complexity: Andrea discusses the pros and cons of random integration, highlighting how it can become a bottleneck. She emphasizes the importance of choosing the right methodology from the very beginning to avoid the "needle in a haystack" scenario when searching for a good clone.
Modern Tools for Ensuring Clonality: Technologies like imaging devices and single-cell dispensers have revolutionized the process. Learn about the shift from traditional limiting dilution methods to more sophisticated and efficient tools that provide better evidence for regulatory approval.
Innovative Approaches to Accelerate Development: Discover how semi-targeted integration methods like transposon technology can significantly shorten timelines and improve clone stability. Andrea also explores the use of bulk pools to generate initial products quickly for pre-clinical and initial clinical studies.

Developing cell lines is a complex process, but with advanced tools and innovative approaches, challenges can become opportunities. As biotechnology progresses, the ability to stay informed and flexible will remain essential for success.

Catch the full episode to gain deeper insights and practical advice for advancing your cell line development projects!

Join us for the next episode featuring Andrea Gough, as we explore how AI and machine learning are being integrated into the early stages of clone selection. This groundbreaking approach is transforming key areas of biotechnology, including cell line development (CLD).

Connect with Andrea Gough:

LinkedIn: www.linkedin.com/in/andrea-gough-72915282

Advanced Instruments: www.aicompanies.com

Next Steps:

Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech/p/book-a-11-call-with-me-j4vhuo6t

116: Revolutionizing Biologics Development with Hyper Throughput Screening and AI with Jeremy Agresti - Part 2

19 december 2024 | 17 min

Send us a text

The intersection of artificial intelligence and biology presents immense opportunities for transforming bioprocess development. As the biotech industry continues to evolve, data-driven innovations are critical to optimizing biologics manufacturing. High-quality datasets stand at the forefront of this transformation, empowering researchers to make informed predictions and advance therapeutic discoveries. As AI tools become more commoditized, the focus shifts toward generating robust and extensive datasets to maximize the potential of machine learning in biological applications.

Miniaturization has emerged as a vital enabler in this data-driven approach. Miniaturized systems allow researchers to conduct thousands of tests in an area no larger than the palm of your hand. This drastic reduction in material and resource requirements makes high-throughput screening feasible, economical, and scalable.

Traditional liquid handling robots can manage thousands of tests per day, but each test requires considerable amounts of material, usually leading to high costs. Conventional systems can cost anywhere from $10 to $100 to get a single genotype sequence from discovery to sequencing. Miniaturization can bring these costs down to mere pennies per data point, making it possible to scale the dataset size exponentially.

Key takeaways from our discussion:

The future of AI in biology relies heavily on large, well-annotated datasets. Without them, the full potential of AI remains untapped. High-quality data enables more accurate predictions of protein structures and functions.
Success in bioprocess development often involves collaboration with partners across the value chain. By working together, companies can leverage their unique strengths and expertise to overcome barriers and innovate more efficiently.
Advancements in miniaturization technology allow for high throughput screening at reduced costs. This shift makes it viable to generate large datasets, speeding up the pace of discovery and making AI-driven predictions more accessible.

This episode is essential for anyone eager to explore the transformative fusion of AI and biotechnology. Jeremy Agresti highlights the future of bioprocessing at the intersection of high-throughput screening, miniaturization, and AI, revealing how these innovations are solving complex challenges, driving breakthroughs, and shaping the future of science and medicine.

Connect with Jeremy Agresti:

LinkedIn: www.linkedin.com/in/jeremy-agresti-88546850/

Triplebar: www.triplebar.com

Next Steps:

Overwhelmed by complex bioprocess development decisions? Get strategic guidance to avoid costly mistakes and stay ahead: https://bruehlmann-consulting.com

Are soaring manufacturing costs keeping your lifesaving therapies out of reach for patients? Book your free assessment at: https://bruehlmann-consulting.com/assessment

115: Revolutionizing Biologics Development with Hyper Throughput Screening and AI with Jeremy Agresti - Part 1

17 december 2024 | 20 min

Send us a text

Bioprocess development is transforming the biotech industry, driving innovations in life-changing therapies. Success hinges on simplifying complex mechanisms and adopting advanced technologies. By integrating high-throughput screening and artificial intelligence, we can streamline workflows, reduce trial-and-error, and speed up biologics development. Embracing cutting-edge tools empowers scientists to maximize biology's potential, delivering efficient and impactful biotech solutions.

In this episode of The Smart Biotech Scientist Podcast, host David Brühlmann explores these transformative methodologies with Jeremy Agresti, CTO and founder of Triplebar.

Jeremy highlights the future of bioprocessing at the intersection of high-throughput screening, miniaturization, and AI. With tools that enhance predictability, scalability, and efficiency, Triplebar is set to transform biotechnology. By reimagining traditional methods, improving inputs, and leveraging modern technology, companies like Triplebar are driving a new era in bioprocessing, offering innovative solutions to complex biological challenges.

Key Takeaways:

Jeremy challenges the traditional view of scale-up issues, emphasizing that many problems can be solved at a smaller scale with better engineered strains and cell lines.

By creating tiny bioreactors of droplets, Triplebar is able to perform high throughput screening, testing millions of mutations quickly and efficiently, and providing robust solutions for complex biological functions.

The integration of massive data sets with AI allows for improved enzyme and protein design, unlocking the potential to innovate even when foundational understanding is limited.

Ready to dive deeper? Join the journey of transforming bioprocess development with smart insights and pioneering spirit. Catch up with Jeremy’s full story via the latest episode of the Smart Biotech Scientist podcast.

Connect with Jeremy Agresti:

LinkedIn: www.linkedin.com/in/jeremy-agresti-88546850/

Triplebar: www.triplebar.com

Next Steps:

Overwhelmed by complex bioprocess development decisions? Get strategic guidance to avoid costly mistakes and stay ahead: https://bruehlmann-consulting.com

Are soaring manufacturing costs keeping your lifesaving therapies out of reach for patients? Book your free assessment at: https://bruehlmann-consulting.com/assessment

114: Weighing of Single-Use Bag Systems: Why Traditional Load Cells Are Holding You Back with Anders Tvegaard - Part 2

12 december 2024 | 18 min

113: Weighing of Single-Use Bag Systems: Why Traditional Load Cells Are Holding You Back with Anders Tvegaard - Part 1

10 december 2024 | 22 min

112: AI Meets Biology: Why Domain Expertise Still Rules in the Age of Large Language Models with Lars Brandén - Part 2

5 december 2024 | 24 min

111: AI Meets Biology: Why Domain Expertise Still Rules in the Age of Large Language Models with Lars Brandén - Part 1

3 december 2024 | 19 min

110: Spinning Like Earth: Designing Low-Shear Bioreactors for Better Cell Culture with Olivier Detournay - Part 2

28 november 2024 | 16 min

109: Spinning Like Earth: Designing Low-Shear Bioreactors for Better Cell Culture with Olivier Detournay - Part 1

26 november 2024 | 19 min

108: From 1 Billion to 100: How AI is Cracking the Enzyme Discovery Code with David Schönauer - Part 2

21 november 2024 | 27 min

107: From 1 Billion to 100: How AI is Cracking the Enzyme Discovery Code with David Schönauer - Part 1

19 november 2024 | 19 min

106: From Proteins to Cell Therapy: Why ATMPs Aren't Just Complex Biologics with Oliver Kraemer - Part 2

14 november 2024 | 20 min

105: From Proteins to Cell Therapy: Why ATMPs Aren't Just Complex Biologics with Oliver Kraemer - Part 1

12 november 2024 | 22 min

104: One-Stop Shop vs. Specialist CDMO: A Scientist's Guide to CDMO Selection with Sigma Mostafa - Part 2

7 november 2024 | 17 min

103: One-Stop Shop vs. Specialist CDMO: A Scientist's Guide to CDMO Selection with Sigma Mostafa - Part 1

5 november 2024 | 24 min

102: PAT Revolution: Decoding Your Bioprocess Like Never Before with Katharina Dahlmann - Part 2

31 oktober 2024 | 15 min

101: PAT Revolution: Decoding Your Bioprocess Like Never Before with Katharina Dahlmann - Part 1

29 oktober 2024 | 23 min

100: From Raw Data to Actionable Insights: Unlocking the Power of Process Models with Fabian Feidl - Part 2

24 oktober 2024 | 18 min

99: From Raw Data to Actionable Insights: Unlocking the Power of Process Models with Fabian Feidl - Part 1

22 oktober 2024 | 22 min

98: The Biomanufacturing Revolution: Bringing Game-changing Products to Market with James Ryall - Part 2

17 oktober 2024 | 18 min

97: The Biomanufacturing Revolution: Bringing Game-changing Products to Market with James Ryall - Part 1

15 oktober 2024 | 24 min

96: AI in Bioprocess Development: The Game-Changer You Can't Ignore with Belma Alispahic - Part 2

10 oktober 2024 | 20 min

95: AI in Bioprocess Development: The Game-Changer You Can't Ignore with Belma Alispahic - Part 1

8 oktober 2024 | 21 min

94: From Lab Coat to LinkedIn: Benjamin McLeod's Journey to Cell and Gene Therapy Influencer - Part 2

3 oktober 2024 | 20 min

93: From Lab Coat to LinkedIn: Benjamin McLeod's Journey to Cell and Gene Therapy Influencer - Part 1

1 oktober 2024 | 24 min

92: Mass Transfer Secrets: Mastering Bubbles and kLa from Bench to Large-Scale Production with Lars Puiman & Rik Volger - Part 2

26 september 2024 | 16 min

91: Mass Transfer Secrets: Mastering Bubbles and kLa from Bench to Large-Scale Production with Lars Puiman & Rik Volger - Part 1

24 september 2024 | 17 min

90: Scale-Up Secrets: Cracking the Code of AAV Production with Ahmed Youssef - Part 2

19 september 2024 | 25 min

89: Scale-Up Secrets: Cracking the Code of AAV Production with Ahmed Youssef - Part 1

17 september 2024 | 20 min

88: The Swiss Army Knife of Biotech: Unleashing the Power of Fractional Expertise

12 september 2024 | 17 min

87: The Hidden Pitfalls of Bioprocess Development: Lessons from the Trenches

10 september 2024 | 17 min

86: Bioprocess 4.0: Integrated Continuous Biomanufacturing with Massimo Morbidelli - Part 2

5 september 2024 | 23 min

85: Bioprocess 4.0: Integrated Continuous Biomanufacturing with Massimo Morbidelli - Part 1

3 september 2024 | 24 min

84: The Hidden Potential of Shake Flasks: What Every Biotech Scientist Needs to Know with Jens Bayer - Part 2

29 augusti 2024 | 23 min

83: The Hidden Potential of Shake Flasks: What Every Biotech Scientist Needs to Know with Jens Bayer - Part 1

27 augusti 2024 | 18 min

82: Regenerating Muscles: The Future of Autologous Cell-based Therapy with Deana Mohr - Part 2

22 augusti 2024 | 18 min

81: Regenerating Muscles: The Future of Autologous Cell-based Therapy with Deana Mohr - Part 1

20 augusti 2024 | 23 min

80: Think Before You Build: Holistic Approaches to Biotech Facility Design with Alfredo Martínez Mogarra - Part 2

15 augusti 2024 | 20 min

79: Think Before You Build: Holistic Approaches to Biotech Facility Design with Alfredo Martínez Mogarra - Part 1

13 augusti 2024 | 24 min

78: Cell Factories Explained: How Synthetic Biology and AI Revolutionize Protein Production with Mauro Torres - Part 2

8 augusti 2024 | 18 min

77: Cell Factories Explained: How Synthetic Biology and AI Revolutionize Protein Production with Mauro Torres - Part 1

6 augusti 2024 | 23 min

76: Transforming Single-Cell Analysis With Impedance Flow Cytometry w/ Furkan Gökçe - Part 2

1 augusti 2024 | 23 min

75: Transforming Single-Cell Analysis With Impedance Flow Cytometry w/ Furkan Gökçe - Part 1

30 juli 2024 | 17 min

74: Bead-Based Assays: The Power of High-Throughput Screening w/ Sebastian Giehring - Part 2

25 juli 2024 | 17 min

73: Bead-Based Assays: The Power of High-Throughput Screening w/ Sebastian Giehring - Part 1

23 juli 2024 | 19 min

72: Effective Outsourcing: How Small Biotech Companies Can Thrive w/ Mark Melville - Part 2

18 juli 2024 | 22 min

71: Effective Outsourcing: How Small Biotech Companies Can Thrive w/ Mark Melville - Part 1

16 juli 2024 | 19 min

70: Glycoanalytics Explained: Analysing and Designing Better Biopharmaceutical Drugs w/ Róisín O’Flaherty - Part 2

11 juli 2024 | 16 min

69: Glycoanalytics Explained: Analysing and Designing Better Biopharmaceutical Drugs w/ Róisín O’Flaherty - Part 1

9 juli 2024 | 18 min

68: How Process Mapping Transforms Knowledge Management in Biotech w/ Irwin Hirsh - Part 2

4 juli 2024 | 29 min

67: How Process Mapping Transforms Knowledge Management in Biotech w/ Irwin Hirsh - Part 1

2 juli 2024 | 14 min

66: Freezing and Thawing Cells: the Science Behind Cryopreservation w/ Mark Davison - Part 2

27 juni 2024 | 16 min

65: Freezing and Thawing Cells: the Science Behind Cryopreservation w/ Mark Davison - Part 1

25 juni 2024 | 24 min

64: Why Sound Waves Are the Future of Gene Therapy Bioreactors w/ Gabriel Dumy - Part 2

20 juni 2024 | 22 min

63: Why Sound Waves Are the Future of Gene Therapy Bioreactors w/ Gabriel Dumy - Part 1

18 juni 2024 | 25 min

62: Magnetic Bead Technology: The New Era in Downstream Processing w/ Nils Brechmann - Part 2

13 juni 2024 | 15 min

61: Magnetic Bead Technology: The New Era in Downstream Processing w/ Nils Brechmann - Part 1

11 juni 2024 | 19 min

60: Next-Generation Sequencing: Transforming Science and Medicine w/ Jonathon Hill - Part 2

6 juni 2024 | 21 min

59: Next-Generation Sequencing: Transforming Science and Medicine w/ Jonathon Hill - Part 1

4 juni 2024 | 17 min

58: Crafting a Solid CMC Strategy: Key Factors and Common Pitfalls w/ Matthias Müllner - Part 2

30 maj 2024 | 19 min

57: Crafting a Solid CMC Strategy: Key Factors and Common Pitfalls w/ Matthias Müllner - Part 1

28 maj 2024 | 17 min

56: Cultivated Meat: A Promising Future or an Inevitable Bubble? w/ Steven Lang - Part 2

23 maj 2024 | 15 min

55: Cultivated Meat: A Promising Future or an Inevitable Bubble? /w Steven Lang - Part 1

21 maj 2024 | 23 min

54: Bionic Bioreactors: The Key to Stress-Free Cell Cultivation w/ Patrick Bongartz - Part 2

16 maj 2024 | 19 min

53: Bionic Bioreactors: The Key to Stress-Free Cell Cultivation w/ Patrick Bongartz - Part 1

14 maj 2024 | 18 min

52: Unraveling the Complexity of Commercializing Cell and Gene Therapies w/ Wajiha Ali - Part 2

9 maj 2024 | 26 min

51: Unraveling the Complexity of Commercializing Cell and Gene Therapies w/ Wajiha Ali - Part 1

7 maj 2024 | 19 min

50: Decode Bioprocess Success: The Art of Stakeholder Management - Part 2

2 maj 2024 | 11 min

49: Decode Bioprocess Success: The Art of Stakeholder Management - Part 1

30 april 2024 | 17 min

48: Mastering Process Economics: Driving Down Costs in Antibody Production w/ Brian Kelley - Part 2

25 april 2024 | 19 min

47: Mastering Process Economics: Driving Down Costs in Antibody Production w/ Brian Kelley - Part 1

23 april 2024 | 17 min

46: From Lab to Table: The Science Behind Cultivated Meat w/ Petra Hanga - Part 2

18 april 2024 | 26 min

45: From Lab to Table: The Science Behind Cultivated Meat w/ Petra Hanga - Part 1

16 april 2024 | 14 min

44: Mastering the Art and Science of Glycan Engineering in Drug Development w/ Henning von Horsten - Part 2

11 april 2024 | 18 min

43: Mastering the Art and Science of Glycan Engineering in Drug Development w/ Henning von Horsten - Part 1

9 april 2024 | 23 min

42: Revealing the Disciplined Pursuit of Less in Bioprocessing - Part 2

4 april 2024 | 13 min

41: Revealing the Disciplined Pursuit of Less in Bioprocessing - Part 1

2 april 2024 | 15 min

40: Balancing Perfusion Process Development and Sustainability w/ Jochen Sieck - Part 2

28 mars 2024 | 15 min

39: Balancing Perfusion Process Development and Sustainability w/ Jochen Sieck - Part 1

26 mars 2024 | 24 min

38: How to Master Downstream: A Deep Dive Into Bioprocessing Purification w/ Wei Zhang - Part 2

21 mars 2024 | 17 min

37: How to Master Downstream: A Deep Dive Into Bioprocessing Purification w/ Wei Zhang - Part 1

19 mars 2024 | 20 min

36: Smart Biotech Development Strategies for Adherent Cell Culture w/ Joel Eichmann - Part 2

14 mars 2024 | 18 min

35: Smart Biotech Development Strategies for Adherent Cell Culture w/ Joel Eichmann - Part 1

12 mars 2024 | 19 min

34: The 7 Habits of Highly Successful Innovators - Part 2

7 mars 2024 | 11 min

33: The 7 Habits of Highly Successful Innovators - Part 1

5 mars 2024 | 11 min

32: The Future of Glycoengineering: Trends Unveiled w/ Thomas Rexer - Part 2

29 februari 2024 | 17 min

31: The Future of Glycoengineering: Trends Unveiled w/ Thomas Rexer - Part 1

27 februari 2024 | 18 min

30: From Monoclonals to Gene Therapy: Tips for Biopharma Process Development w/ Neil Templeton - Part 2

22 februari 2024 | 15 min

29: From Monoclonals to Gene Therapy: Tips for Biopharma Process Development w/ Neil Templeton - Part 1

20 februari 2024 | 23 min

28: How to Simplify Project Management in Bioprocess Development - Part 2

15 februari 2024 | 13 min

27: How to Simplify Project Management in Bioprocess Development - Part 1

13 februari 2024 | 16 min

26: 9 Critical Steps for a Seamless Transition to Large-Scale Production - Part 2

8 februari 2024 | 13 min

25: 9 Critical Steps for a Seamless Transition to Large-Scale Production - Part 1

6 februari 2024 | 19 min

24: Strategies for Success: Master CMC Development with Gene Lee - Part 2

1 februari 2024 | 23 min

23: Strategies for Success: Master CMC Development with Gene Lee - Part 1

30 januari 2024 | 18 min

22: Unleashing Effective QbD Strategies to Master Cell Therapy with Shin Kawamata - Part 2

25 januari 2024 | 19 min

21: Unleashing Effective QbD Strategies to Master Cell Therapy with Shin Kawamata - Part 1

23 januari 2024 | 22 min

20: How to Take Your Molecule From the Lab to Clinical Trials w/ Bernardo Estupiñán Gaisbauer - Part 2

18 januari 2024 | 17 min

19: How to Take Your Molecule From the Lab to Clinical Trials w/ Bernardo Estupiñán Gaisbauer - Part 1

16 januari 2024 | 20 min

18: How Extracting Gold From Your Data Accelerates Process Development w/ Ioscani Jiménez del Val - Part 2

11 januari 2024 | 14 min

17: How Extracting Gold From Your Data Accelerates Process Development w/ Ioscani Jiménez del Val - Part 1

9 januari 2024 | 19 min

16: Bacon Without Pigs? Innovations in Cultivated Meat Manufacturing with Beat Thalmann - Part 2

21 december 2023 | 20 min

15: Bacon Without Pigs? Innovations in Cultivated Meat Manufacturing with Beat Thalmann - Part 1

19 december 2023 | 18 min

14: Digital Transformation in Biomanufacturing: A Rapidly Moving Tech Frontier w/ Abhijeet Satwekar - Part 2

14 december 2023 | 17 min

13: Digital Transformation in Biomanufacturing: A Rapidly Moving Tech Frontier w/ Abhijeet Satwekar - Part 1

12 december 2023 | 17 min

12: From Lab to Patient: Steve Oh’s Guide to Mastering Cell Therapy Process Development - Part 2

7 december 2023 | 17 min

11: From Lab to Patient: Steve Oh’s Guide to Mastering Cell Therapy Process Development - Part 1

5 december 2023 | 25 min

10: Revolutionizing Cell-Line Development: Unleashing the Power of Nanopens and Microenvironments w/ Tanner Nevill - Part 2

30 november 2023 | 16 min

09: Revolutionizing Cell-Line Development: Unleashing the Power of Nanopens and Microenvironments w/ Tanner Nevill - Part 1

28 november 2023 | 14 min

08: Unveiling the Power of Microcarriers: Scaling Up Adherent Cell Cultures in Bioprocessing w/ Payar Radfar - Part 2

23 november 2023 | 13 min

07: Unveiling the Power of Microcarriers: Scaling Up Adherent Cell Cultures in Bioprocessing w/ Payar Radfar - Part 1

21 november 2023 | 16 min

06: Hybrid Modeling: The Key to Smarter Bioprocessing w/ Michael Sokolov - Part 2

16 november 2023 | 19 min

05: Hybrid Modeling: The Key to Smarter Bioprocessing w/ Michael Sokolov - Part 1

14 november 2023 | 17 min

04: How to Master Biotech Scale-up Without Guesswork w/ Leonardo Sibilio - Part 2

9 november 2023 | 13 min

01: Unlock the Power of Rational Media Design in Bioprocessing w/ Tom Fletcher - Part 1

7 november 2023 | 18 min

02: Unlock the Power of Rational Media Design in Bioprocessing w/ Tom Fletcher - Part 2

7 november 2023 | 16 min

03: How to Master Biotech Scale-up Without Guesswork w/ Leonardo Sibilio - Part 1

7 november 2023 | 17 min

Biotech Simplified: Your Path to Bioprocess Mastery Unveiled (Trailer)

31 oktober 2023 | 3 min

Smart Biotech Scientist | Master Bioprocess CMC Development, Biologics Manufacturing & Scale-up for Busy Scientists

The Go-to Podcast for Biotech Scientists Who Want to Master Bioprocess CMC Development and Manufacturing of Biologics.

Om podden

Avsnitt

130: Revolutionizing Cell Therapy Manufacturing: Reducing Costs to Reach More Patients with Jason Foster - Part 2

129: Revolutionizing Cell Therapy Manufacturing: Reducing Costs to Reach More Patients with Jason Foster - Part 1

128: The 7 Hidden Innovation Habits That Top Biotech Scientists Use Daily - Part 2

127: The 7 Hidden Innovation Habits That Top Biotech Scientists Use Daily - Part 1

126: How to Enhance Cell Engineering Using Mechanical Intracellular Delivery with Armon Sharei - Part 2

125: How to Enhance Cell Engineering Using Mechanical Intracellular Delivery with Armon Sharei - Part 1

124: Manufacturability: Why Most Protein Candidates Fail (And How to Pick Winners Early) with Susan Sharfstein - Part 2

123: Manufacturability: Why Most Protein Candidates Fail (And How to Pick Winners Early) with Susan Sharfstein - Part 1

122: The Transformative World of Digital Solutions in Bioprocessing with Simon Wieninger - Part 2

121: The Transformative World of Digital Solutions in Bioprocessing with Simon Wieninger - Part 1

120: Innovating Protein Purification Using Synthetic Organelles and AI with Haotian Guo - Part 2

119: Innovating Protein Purification Using Synthetic Organelles and AI with Haotian Guo - Part 1

118: Critical Bottlenecks and Breakthroughs in Cell Line Development with Andrea Gough - Part 2

117: Critical Bottlenecks and Breakthroughs in Cell Line Development with Andrea Gough - Part 1

116: Revolutionizing Biologics Development with Hyper Throughput Screening and AI with Jeremy Agresti - Part 2

115: Revolutionizing Biologics Development with Hyper Throughput Screening and AI with Jeremy Agresti - Part 1

114: Weighing of Single-Use Bag Systems: Why Traditional Load Cells Are Holding You Back with Anders Tvegaard - Part 2

113: Weighing of Single-Use Bag Systems: Why Traditional Load Cells Are Holding You Back with Anders Tvegaard - Part 1

112: AI Meets Biology: Why Domain Expertise Still Rules in the Age of Large Language Models with Lars Brandén - Part 2

111: AI Meets Biology: Why Domain Expertise Still Rules in the Age of Large Language Models with Lars Brandén - Part 1

110: Spinning Like Earth: Designing Low-Shear Bioreactors for Better Cell Culture with Olivier Detournay - Part 2

109: Spinning Like Earth: Designing Low-Shear Bioreactors for Better Cell Culture with Olivier Detournay - Part 1

108: From 1 Billion to 100: How AI is Cracking the Enzyme Discovery Code with David Schönauer - Part 2

107: From 1 Billion to 100: How AI is Cracking the Enzyme Discovery Code with David Schönauer - Part 1

106: From Proteins to Cell Therapy: Why ATMPs Aren't Just Complex Biologics with Oliver Kraemer - Part 2

105: From Proteins to Cell Therapy: Why ATMPs Aren't Just Complex Biologics with Oliver Kraemer - Part 1

104: One-Stop Shop vs. Specialist CDMO: A Scientist's Guide to CDMO Selection with Sigma Mostafa - Part 2

103: One-Stop Shop vs. Specialist CDMO: A Scientist's Guide to CDMO Selection with Sigma Mostafa - Part 1

102: PAT Revolution: Decoding Your Bioprocess Like Never Before with Katharina Dahlmann - Part 2

101: PAT Revolution: Decoding Your Bioprocess Like Never Before with Katharina Dahlmann - Part 1

100: From Raw Data to Actionable Insights: Unlocking the Power of Process Models with Fabian Feidl - Part 2

99: From Raw Data to Actionable Insights: Unlocking the Power of Process Models with Fabian Feidl - Part 1

98: The Biomanufacturing Revolution: Bringing Game-changing Products to Market with James Ryall - Part 2

97: The Biomanufacturing Revolution: Bringing Game-changing Products to Market with James Ryall - Part 1

96: AI in Bioprocess Development: The Game-Changer You Can't Ignore with Belma Alispahic - Part 2

95: AI in Bioprocess Development: The Game-Changer You Can't Ignore with Belma Alispahic - Part 1

94: From Lab Coat to LinkedIn: Benjamin McLeod's Journey to Cell and Gene Therapy Influencer - Part 2

93: From Lab Coat to LinkedIn: Benjamin McLeod's Journey to Cell and Gene Therapy Influencer - Part 1

92: Mass Transfer Secrets: Mastering Bubbles and kLa from Bench to Large-Scale Production with Lars Puiman & Rik Volger - Part 2

91: Mass Transfer Secrets: Mastering Bubbles and kLa from Bench to Large-Scale Production with Lars Puiman & Rik Volger - Part 1

90: Scale-Up Secrets: Cracking the Code of AAV Production with Ahmed Youssef - Part 2

89: Scale-Up Secrets: Cracking the Code of AAV Production with Ahmed Youssef - Part 1

88: The Swiss Army Knife of Biotech: Unleashing the Power of Fractional Expertise

87: The Hidden Pitfalls of Bioprocess Development: Lessons from the Trenches

86: Bioprocess 4.0: Integrated Continuous Biomanufacturing with Massimo Morbidelli - Part 2

85: Bioprocess 4.0: Integrated Continuous Biomanufacturing with Massimo Morbidelli - Part 1

84: The Hidden Potential of Shake Flasks: What Every Biotech Scientist Needs to Know with Jens Bayer - Part 2

83: The Hidden Potential of Shake Flasks: What Every Biotech Scientist Needs to Know with Jens Bayer - Part 1

82: Regenerating Muscles: The Future of Autologous Cell-based Therapy with Deana Mohr - Part 2

81: Regenerating Muscles: The Future of Autologous Cell-based Therapy with Deana Mohr - Part 1

80: Think Before You Build: Holistic Approaches to Biotech Facility Design with Alfredo Martínez Mogarra - Part 2

79: Think Before You Build: Holistic Approaches to Biotech Facility Design with Alfredo Martínez Mogarra - Part 1

78: Cell Factories Explained: How Synthetic Biology and AI Revolutionize Protein Production with Mauro Torres - Part 2

77: Cell Factories Explained: How Synthetic Biology and AI Revolutionize Protein Production with Mauro Torres - Part 1

76: Transforming Single-Cell Analysis With Impedance Flow Cytometry w/ Furkan Gökçe - Part 2

75: Transforming Single-Cell Analysis With Impedance Flow Cytometry w/ Furkan Gökçe - Part 1

74: Bead-Based Assays: The Power of High-Throughput Screening w/ Sebastian Giehring - Part 2

73: Bead-Based Assays: The Power of High-Throughput Screening w/ Sebastian Giehring - Part 1

72: Effective Outsourcing: How Small Biotech Companies Can Thrive w/ Mark Melville - Part 2

71: Effective Outsourcing: How Small Biotech Companies Can Thrive w/ Mark Melville - Part 1

70: Glycoanalytics Explained: Analysing and Designing Better Biopharmaceutical Drugs w/ Róisín O’Flaherty - Part 2

69: Glycoanalytics Explained: Analysing and Designing Better Biopharmaceutical Drugs w/ Róisín O’Flaherty - Part 1

68: How Process Mapping Transforms Knowledge Management in Biotech w/ Irwin Hirsh - Part 2

67: How Process Mapping Transforms Knowledge Management in Biotech w/ Irwin Hirsh - Part 1

66: Freezing and Thawing Cells: the Science Behind Cryopreservation w/ Mark Davison - Part 2

65: Freezing and Thawing Cells: the Science Behind Cryopreservation w/ Mark Davison - Part 1

64: Why Sound Waves Are the Future of Gene Therapy Bioreactors w/ Gabriel Dumy - Part 2

63: Why Sound Waves Are the Future of Gene Therapy Bioreactors w/ Gabriel Dumy - Part 1

62: Magnetic Bead Technology: The New Era in Downstream Processing w/ Nils Brechmann - Part 2

61: Magnetic Bead Technology: The New Era in Downstream Processing w/ Nils Brechmann - Part 1

60: Next-Generation Sequencing: Transforming Science and Medicine w/ Jonathon Hill - Part 2

59: Next-Generation Sequencing: Transforming Science and Medicine w/ Jonathon Hill - Part 1

58: Crafting a Solid CMC Strategy: Key Factors and Common Pitfalls w/ Matthias Müllner - Part 2

57: Crafting a Solid CMC Strategy: Key Factors and Common Pitfalls w/ Matthias Müllner - Part 1

56: Cultivated Meat: A Promising Future or an Inevitable Bubble? w/ Steven Lang - Part 2

55: Cultivated Meat: A Promising Future or an Inevitable Bubble? /w Steven Lang - Part 1